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Background: Anti-malarial drug resistance in Plasmodium falciparum in India has historically travelled from
northeast India along the Myanmar border. The treatment policy for P. falciparum in the region was, therefore,
changed from chloroquine to artesunate (AS) plus sulphadoxine-pyrimethamine (SP) in selected areas in 2005 and
in 2008 it became the first-line treatment. Recognizing that resistance to the partner drug can limit the useful life of
this combination therapy, routine in vivo and molecular monitoring of anti-malarial drug efficacy through sentinel
sites was initiated in 2009.
Methods: Between May and October 2012, 190 subjects with acute uncomplicated falciparum malaria were
enrolled in therapeutic efficacy studies in the states of Arunachal Pradesh, Tripura, and Mizoram. Clinical and
parasitological assessments were conducted over 42 days of follow-up. Multivariate analysis was used to determine
risk factors associated with treatment failure. Genotyping was done to distinguish re-infection from recrudescence
as well as to determine the prevalence of molecular markers of antifolate resistance among isolates.
Results: A total of 169 patients completed 42 days of follow-up at three sites. The crude and PCR-corrected
Kaplan-Meier survival estimates of AS + SP were 60.8% (95% CI: 48.0-71.4) and 76.6% (95% CI: 64.1-85.2) in Gomati,
Tripura; 74.6% (95% CI: 62.0-83.6) and 81.7% (95% CI: 69.4-89.5) in Lunglei, Mizoram; and, 59.5% (95% CI: 42.0-73.2) and
82.3% (95% CI: 64.6-91.6) in Changlang, Arunachal Pradesh. Most patients with P. falciparum cleared parasitaemia within
24 hours of treatment, but eight, including three patients who failed treatment, remained parasitaemic on day 3. Risk
factors associated with treatment failure included age < five years, fever at the time of enrolment and AS under dosing.
No adverse events were reported. Presence of dhfr plus dhps quintuple mutation was observed predominantly in
treatment failure samples.
Conclusion: AS + SP treatment failure was widespread in northeast India and exceeded the threshold for
changing drug policy. Based on these results, in January 2013 the expert committee of the National Vector
Borne Disease Control Programme formulated the first subnational drug policy for India and selected artemether plus
lumefantrine as the new first-line treatment in the northeast. Continued monitoring of anti-malarial drug efficacy is
essential for effective malaria control.
Keywords: Plasmodium falciparum, Artesunate + sulphadoxine-pyrimethamine (AS + SP), Artemisinin combination
therapy (ACT), Dihydrofolate reductase (dhfr), Dihyropteroate synthase (dhps)* Correspondence: neenavalecha@gmail.com
1ECR Division, National Institute of Malaria Research, ICMR Sector 8, Dwarka,
New Delhi 110 077, India
Full list of author information is available at the end of the article
© 2014 Mishra et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Mishra et al. Malaria Journal 2014, 13:284 Page 2 of 12
http://www.malariajournal.com/content/13/1/284Background
Anti-malarial drug resistance, particularly in Plasmodium
falciparum was a major contributor to global resurgence of
malaria in the 20th Century. Southeast Asia (SEA) has been
the focus of drug resistance for all anti-malarials with loss
of valuable drugs from time to time. Chloroquine resistance
in P. falciparum malaria was first reported in 1957 in SEA
region, later followed by sulphadoxine-pyrimethamine
resistance after ten years [1-3]. India shares international
boundaries with countries known to be the epicentre for
drug resistance. India too experienced increase in falcip-
arum malaria cases with resistance to first-line anti-malarial
chloroquine (CQ) in 1973 in northeast India which later
spread to other areas in the country [4]. However, resistance
to second-line anti-malarial sulphadoxine-pyrimethamine
(SP) was also detected in the same area in the country,
spreading even more rapidly to other parts of the country.
Increasing resistance to CQ and SP forced the national
programme to abandon CQ for treatment of P. falciparum
[5-7], however CQ remains the first-line anti-malarial treat-
ment for Plasmodium vivax, another parasite that contrib-
utes equally to human malaria in the country.
Since 2005, treatment of uncomplicated P. falciparum
malaria in the country is based on artemisinin combin-
ation therapy (ACT) as per the recommendation of World
Health Organization (WHO) [8]. The ACT recommended
in the country is artesunate plus SP. Presently, all the
five formulations of ACT recommended by WHO except
dihydroartemisinin [DHA] + piperaquine, are registered
with the Drugs Controller General of India. Prior to intro-
duction of ACT in the country, SP has been used for the
treatment of uncomplicated falciparum malaria in India
since 1980s as second line [9]. However, resistance to part-
ner drug SP has already been reported in the country
[10], which threatens the useful life of this ACT. The
mechanism of SP resistance has been well documented
compared to other anti-malarials. Point mutations in the
dihydropteroate synthase (dhps) and dihydrofolate reduc-
tase (dhfr) genes, both coding for essential enzymes in the
folate biosynthesis pathway, led to resistance to antifolate
drugs [11].
Recent reports on artemisinin resistance in the SEA
region [12] also required continuous monitoring of ACT
in the country. Artemisinin resistance, defined by delayed
parasite clearance following complete treatment, was first
reported in SEA along the Thai-Cambodia border in 2006
[12,13]. Recently, parasites with much slower clearance
profiles have also been identified in Western Thailand
on the border with Myanmar, along the Myanmar-China
border and in Vietnam [14-17].
The Indian northeastern region has varied ecological
diversity, inaccessible areas where vector control mea-
sures as well early treatment and diagnosis facilities are
difficult to assess. Malaria control remains a challenge inthese areas. ACT was introduced in the study areas in
2007 and since 2009 continuous monitoring of recom-
mended anti-malarials has been done through nationwide
sentinel site system. Also, partner drug resistance markers
(dhfr plus dhps) are potential early warning signs; the same
were also monitored for the study sites which prompted
more focus in these study areas.
This study was part of nationwide sentinel site system
initiated in 2009 with the aim to address the continued
problem of anti-malarial drug resistance in the country.
Continuous monitoring of ACT efficacy was done at the
developed sentinel sites. This study reports the findings
of the clinical as well as molecular studies at three study
sites in the northeastern region.
Methods
Study sites
The study was conducted from May to August 2012 in
Mizoram (district Lunglei, Tlabung Sub divisional hos-
pital); from August to September 2012 in Tripura (district
Gomati, Silachari Primary Health Centre (PHC)); from
September to October 2012 in Arunachal Pradesh (district
Changlang, PHC Miao). The study sites (Figure 1), which
include three different regions of northeastern India repre-
senting different epidemiological situation of malaria due
to international borders, are described below.
Mizoram
Lunglei district in the state of Mizoram presents ideal
ecological conditions for malaria transmission with un-
dulating uplands intersected by forested hills, rocky
streams and jhum cultivation land. The area is charac-
terized by a tropical, humid climate with cool summer
and cold winter and heavy rainfall during May to late
September with an average annual rainfall of 3,006 mm
under the influence of southwest monsoon, and the
mean annual temperature ranges between 20 and 26°C.
The state contributes 0.8% to the country’s malaria
burden [18]. Plasmodium falciparum accounts for 80 to
90% of the total malaria cases and the proportion of
P. falciparum has increased from 83 to 96% over the
last five years in the study district. The study area of
Tlabung subdivisional hospital in Lunglei district is
highly endemic for malaria, characterized by year-round
malaria transmission.
Tripura
The state contributes 1.3% to the country’s malaria burden
[18]. The peak malaria season is from August to November.
The study districts are highly endemic, with a high pro-
portion of P. falciparum (87-91%) cases.
Tripura is one of the states in the northeastern region
which shares a long international border with Bangladesh.
The hilly and undulating terrain and the movement of
Figure 1 Details of study site from the National Antimalarial Drug Resistance Monitoring System, northeast India, 2012–2013.
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in villages near the border. The regions adjacent to the
Indo-Bangladesh border are mostly covered with thick for-
ests and have poor communication and health infrastruc-
ture. Plasmodium falciparum is a major malaria parasite
in this region, causing 70 to 90% of malaria infections.
The hot and humid climate in the region is ideal for
survival and multiplication of malaria vectors [19].
Arunachal Pradesh
Changlang district in the state of Arunachal Pradesh is
bounded by Assam and Arunachal Pradesh in the north
and Myanmar in the southeast. The state contributes 1.1%
of the country’s malaria burden [18]. The capital town of
Miao, in Changlang district, was selected as the study sitewhere the percentage of P. falciparum has increased from
56 to 64% in the last five years.
Study design
This was an open-label, one-arm prospective study of clin-
ical and parasitological responses after administration of
ACT treatment and WHO protocol for in vivo monitoring
was followed [20].
Ethical considerations
Informed, written consent was obtained from enrolled
adults and from a legal guardian of each child enrolled. The
study protocol was approved by the Institutional Ethics
Committee of the National Institute of Malaria Research
(NIMR) in New Delhi. These studies were part of
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NIMR and National Vector Borne Disease Control
Programme (NVBDCP) with added quality assurance,
monitoring and molecular markers.
Study population and sample size
Adults and children over 6 months presenting with fever
(axillary temperature ≥ 37.5°C) at visit or a history of
fever for the preceding 24 hours were included in the
study. Other criteria for inclusion were mono-infection
with P. falciparum with parasitaemia between 500 and
100,000 asexual parasites/μl blood, absence of other fe-
brile conditions and informed consent. Patients having
severe malnutrition as per WHO guidelines, severe mal-
aria or danger signs and inability to come for follow-up
visits were excluded from the study.
Treatment and follow-up
Patients with uncomplicated P. falciparum received
artesunate (AS) + SP (AS 4 mg/kg for three days plus
SP 25/1.25 mg/kg single dose on day 0) and primaquine
(PQ) (0.75 mg/kg) on last day of treatment. The treatment
was directly observed on all three days and used quality
assured drugs through state government supply which
consisted of manufacturers (site name in brackets): Medi-
camen Biotech Ltd, India (Lunglei), Medico Remedies Pvt
Ltd, India (Gomati), ZEST Pharma, India (Changlang).
These drugs are supplied in the trade name of ‘Antimalarial
combi blister pack’. All drugs were used within their expiry
period and batch number and expiry dates were recorded
in each case record form (CRF). The dosing was based on
age with five categories of combi blister packs with age cat-
egory < one year, one to four years, five to eight years, nine
to 14 years and >15 years (adult pack). The study followed
the standard WHO protocol for assessment of therapeutic
efficacy of anti-malarial drugs for uncomplicated falciparum
malaria for moderate transmission [20]. On enrolment day
(day 0), upon fulfilment of all inclusion criteria, consent
was obtained from the patients to participate in the study.
A brief history was recorded and clinical was done. A
pretreatment blood sample was collected from each eligible
patient and used to make thick and thin smears and dried
blood spots on filter paper. All medicines were given
under direct supervision. Patients were observed for a few
minutes after administering the study drug to ensure that
they did not vomit. Patients who vomited the dose within
30 minutes were retreated with the same drug and dose.
Follow-ups were scheduled for days 1, 2, 3, 7, 14, 21, 28,
35, and 42. On each of these days, clinical and parasito-
logical assessments were performed. Blood samples were
obtained on filter papers for genotyping and molecular
studies on day 0 and every other day of follow-up. Polymer-
ase chain reaction (PCR) genotyping was done for distin-
guishing recrudescence from new infections by comparingmsp1, msp2 (merozoite surface protein) and glurp (glutam-
ate rich protein) gene loci of pre- and post-treatment sam-
ple pairs. The outcome of treatment with PCR correction
was based on the number of true recrudescence excluding
cases of novel infections. In addition, pfdhfr and pfdhps mu-
tations for partner drug resistance were used as molecular
markers to analyse different samples.
Laboratory methods
Thick and thin blood films were collected and stained
with Giemsa. Slides were examined on day 0 by experi-
enced microscopist(s) for species identification and quan-
tification of parasites. Slides were also prepared on days 1,
2, 3, 7, 14, 21, 28, 35, and 42 to determine asexual and sex-
ual parasite density by counting the number of parasites
against 200 white blood cells (WBCs), and were expressed
assuming WBC count to be 8,000/microlitre. A slide was
considered negative when counting 1,000 WBC in thick
smear did not show asexual parasites. All the slides were
cross-checked at NIMR, Delhi.
Paired blood samples of patients collected on day 0
and the day of recurrent parasitaemia (14–42 days) were
analysed sequentially starting with the highest discrimin-
atory marker, msp2 or glurp. The third marker analysed
was msp1 to differentiate recrudescence from new infec-
tions [21]. A new infection is a subsequent occurring
parasitaemia in which all the alleles in parasites from the
post-treatment sample are different from those in the ad-
mission sample, for one or more loci tested. In a ‘recrudes-
cence’ at least one allele at each locus is common to both
paired samples [21]. In addition, SP resistance-associated
markers, namely mutations at codon 51, 59, 108, 164 of
pfdhfr gene and pfdhps gene at codon 436, 437, 540, 581,
613 were also analysed in the day 0 samples.
Genomic DNA was isolated from blood spots using
QIAamp DNA minikit, Germany. Genotyping PCR assays
were carried out following the protocols reported earlier
[22]. Separate nested PCR reactions were performed for
the three allelic families of msp1 (MAD20, K1 and RO33),
two allelic families of msp2 (Fc 27 and Ic) and glurp. Pfdhfr
and pfdhps gene products were PCR amplified using earlier
reported methods [23] and then digested using restriction
enzymes for dhfr and dhps gene. Applied Biosystem ther-
mocycler was used for all PCR amplification reactions.
Digested PCR product (5–8 microlitre) was analysed on
1.5% agarose gel containing ethidium bromide (0.5 μg/ml)
and 0.5X TBE running buffer (pH 8.0). PCR products
were visualized under UV transilluminator (280 nm) and
digitally captured with the help of gel documentation sys-
tem (Alpha Imager EP). Molecular sizes of PCR fragments
were calculated using gene tool (Alpha Inotech, version
3.0.3.0).
The case record forms were completed for each
patient and all the clinical and parasitological data from
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WHO software [20] and both per protocol and Kaplan
Meier analysis were performed to classify response as early
treatment failure (ETF), late treatment failure (LTF) and
adequate clinical and parasitological response (ACPR). In
the secondary analysis, patients were withdrawn or cen-
sored, if classified as new infection by PCR or if PCR was
missing.
Rescue medication
All the patients with ETF or LTF were treated with oral
quinine in standard dose of 10 mg/kg body weight, three
times for seven days. CRFs were used to capture adverse
events, if any.
Data analysis
Patient and demographic variables that could be associ-
ated with treatment failure were investigated. Using the
body weights recorded on day 0, the doses of AS given
to patients with P. falciparum were categorized as be-
ing ≥ 87.5%, < 87.5 to 75% and < 75% of the recommended
dose per kg. The parasite clearance time (PCT) was re-
corded in CRF till day 2 of treatment, although slides
were made on day 3 as well. However the delayed PCT
(PCT ≥ 72 hours) was calculated on day 3 based on the
mean PCT up to day 2 ± SD. Kaplan-Meier survival ana-
lyses of treatment failure and parasite clearance were con-
ducted with and without the results of the PCR-based
identification of the parasitaemia that resulted from post-
treatment re-infection. Log-risk models were used to
evaluate the multivariate associations observed between
risk factors and endpoints. Multivariate analysis was based
on full models that included age, sex, fever at enrolment,
level of parasitaemia at enrolment, infection with a para-
site that harboured any of the investigated mutations in
dhfr or dhps, and AS dose, as well as the interactions
between age and AS dose, age and level of parasitaemia
on enrolment, and between presence of mutations and
level of parasitaemia on enrolment. A complete case (per
protocol) analysis was performed. A strategy of back-
ward elimination was followed in which p-value of < 0.10
and < 0.15, respectively, were used as the cut-offs in elim-
inating individual factors and interaction terms as sta-
tistically significant risk factors for treatment failures.
All data analysis was performed using version 7.2 of a
software package developed by WHO’s Global Malaria
Programme for evaluating therapeutic efficacy or SPSS
version 14.
Results
A total of 190 patients with uncomplicated P. falciparum
receiving AS + SP treatment on first three days and PQ
on last day of treatment were enrolled from Lunglei
district in Mizoram (71), Gomati district in Tripura (77)and Changlang district in Arunachal Pradesh (42), the
three far- flung regions of northeast India. Fifteen patients
were withdrawn after cross-checking due to mix infection,
presence of other species, or out of range parasitaemia at
the time of enrolment. Thus, 175 patients were found to
be eligible, 169 (96.6%) of whom completed the 42 days of
follow-up (Figure 2).
Almost half of the patients were of either sex and were
febrile at the time of enrolment (Table 1) at two sites
except Lunglei. The intake of anti-malarial drug in the
previous week was rare. High gametocyte carriage was
observed in Changlang followed by Gomati and Lunglei
districts. The combined point mutation in dhfr-dhps
gene, indicating partner drug resistance was observed at
all the three sites with majority of isolates showing
multiple mutations.
For calculating the primary and secondary endpoints of
the 169 patients infected with P. falciparum who com-
pleted 42 days of follow-up, 57 patients were initially cate-
gorized as treatment failures. However, when parasites in
paired dried blood spots from these 57 patients were
genotyped by PCR, only 32 (56%) of the patients were
confirmed as treatment failure, 24 were found to have
P. falciparum re-infection and one had P. vivax infec-
tion on day 21. These 32 patients who were confirmed to
have failed AS + SP treatment came from Lunglei (11),
Gomati (15) and Changlang (six) (Table 2). Four ETF oc-
curred in Gomati (Tripura); two patients had parasitaemia
and fever on day 3 while two patients had parasitaemia on
day 2 (parasitaemia on day 2 was > 25% of day 0). The
crude and PCR-corrected Kaplan-Meier survival estimates
were 60.8% (95% CI: 48.0-71.4) and 76.6% (95% CI: 64.1-
85.2) for Gomati (Tripura); 74.6% (95% CI: 62.0-83.6) and
81.7% (95% CI: 69.4-89.5) for Lunglei, Mizoram; and 59.5%
(95% CI: 42.0-73.2) and 82.3% (95% CI: 64.6-91.6) for
Changlang, Arunachal Pradesh, respectively. In general,
the P. falciparum patients treated with AS + SP cleared
their parasitaemia rapidly, 52.1% (88 of 169) in < 24 hours,
35.5% (60 of 169) in intervals of 24 to <48 hours, 8.8% (15
of 169) in 48 to < 72 hours and 4.7% (eight of 169) of the
patients in ≥ 72 hours, respectively (Table 2). The highest
number of patients clearing parasitaemia within <24 hours
was in Lunglei, Mizoram. Even the LTF patients cleared
their parasitaemia rapidly; 14.8% (13 of 88), 16.7% (ten of
60), 40% (six of 15) and 37.5% (three of eight) of the pa-
tients who showed parasite clearance intervals of < 24 hours,
24 to < 48 hours, 48 to < 72 hours and ≥ 72 hours, respect-
ively. Six of the patients from Gomati, Tripura and two
from Changlang, Arunachal Pradesh did not clear their
parasitaemia within 72 hours (Table 2). Three of them were
identified as treatment failures (including two ETF and one
late parasitological failure), two were re-infection whereas
the three achieved complete cure. However, the proportion
of patients remaining parasite positive at day 3 in these
190 patients 
enrolled 
Inclusion criteria violation 
7 Mixed infections 
4 Density range 
4 Other species
Eligible 
175 P. falciparum   
Withdrawals 
   4 consent withdrawals 
1 outside treatment 
1 loss to follow-up
Completed follow-
up










24 P. falciparum reinfection  






Figure 2 Patient cohort from the National Antimalarial Drug Resistance Monitoring System, northeast India, 2012–2013. Abbreviations:
ACPR, adequate clinical and parasitological response; ETF, early treatment failure; LCF, late clinical failure; LPF, late parasitological failure; PCR,
polymerase chain reaction.
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No adverse effect was noted at any site during the 42 days’
follow-up.
The study compared the mean parasitaemia at enrol-
ment, dose of AS or any adverse event reported between
patients who had parasitaemia ≥72 hours with those
who cleared parasite within 48 hours. No significant dif-
ference was observed between the two groups. However,
host immunity had a definite role as six out of eight
patients were < five years of age.In multivariate analysis, younger age category (< five
years) relative to adults 15 years or older and low ad-
ministered dose of AS (< 3 mg/kg, 3–3.5 mg/kg) relative
to 3.5 mg/kg or more were associated with higher risk.
The risk of failure increased as the dose of AS decreased.
However, optimal or higher dose of SP was observed in
90.6% patients. Fever at enrolment was positively and sig-
nificantly associated with treatment failures. Also, relative
risk was highest with the presence of triple or quadruples
mutation (Table 3). There were insufficient observations
Table 1 Clinical and demographic characteristics of eligible patients in studies of the National Antimalarial Drug
Resistance Monitoring System, northeast India, 2012-13
Study site Lunglei (Mizoram) Gomati (Tripura) Changlang (Arunachal Pradesh)
Characteristic (N = 66) (N = 72) (N = 37)
Sex (no (%))
Male 39 (59.1) 39 (54.2) 22 (59.5)
Female 27 (40.9) 33 (45.8) 15 (40.5)
Age category (no (%))
< 5 yr 6 (9.1) 24 (33.3) 7 (18.9)
5-15 yr 26 (39.4) 30 (41.7) 18 (48.6)
Adult 34 (51.5) 18 (25.0) 12 (32.4)
Temperature (˚C)
Mean ± SD 36.3 ± 1.3 38.1 ± 0.4 38.2 ± 0.5
Range 36.2-39.3 37.5 - 39.2 (37.5 - 39.1)
Febrile (≥ 37.5)
Yes (no (%)) 13 (19.7) 72 (100.0) 37 (100.0)
No (no (%)) 53 (80.3) - -
Parasite count (no/μl)a
Mean ± SD 18899.3 ± 23979.5 18507.6 ± 20937.3 31186.5 ± 27451.6
< 5,000 22 (33.3) 26 (36.1) 7 (18.9)
5,000-50,000 36 (54.5) 37 (51.4) 20 (54.1)
≥ 50,000 8 (12.1) 9 (12.5) 10 (27.0)
Gametocytes on day 0
(no (%)) 3 (4.2) 17 (23.9) 12 (32.4)
Number of mutations
0-2 6 (9.1) 3 (4.2) 1 (2.7)
2-4 4 (6.1) 5 (6.9) 2 (5.4)
≥ 5 56 (84.8) 64 (88.9) 34 (91.9)
aAt enrolment, before treatment.
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of ≥ 72 hours.
Gametocytes on day 0 at the enrolment were reported
in 20.1% patients with highest number in Changlang
followed by Gomati. There was increase in the number
of patients carrying gametocytes on day 7 at Gomati,Table 2 Site-wise results of therapeutic efficacy and parasite
Resistance Monitoring System, northeast India, 2012-2013
Therapeutic efficacy
State/UT District/city Drug n ACPRa ETFb LCFc LPFd L
Tripura Gomati ASP 77 43 4 3 8 0
Mizoram Lunglei ASP 71 47 0 3 8 1
Arunachal Pradesh Changlang ASP 42 22 0 2 4 0
Abbreviations: ACPR adequate clinical and parasitological response, ETF early treatm
follow-up, WTH withdrawal, PCT parasite clearance time, *PF P. falciparum re-infectio
aAbsence of parasitaemia on day 28 without previous criteria for failure.
bMarked by the following, alone or in combination: danger signs for severe malaria
higher than on day 0; parasitaemia level on day 3 more than 25% higher than on d
cDanger signs for sever malaria and/or fever plus parasitaemia from day 4 to day 28
dParasitaemia from day 7 to day 28 even if patient afebrile.Tripura (Table 4). The presence of gametocyte was ob-
served in 2.3% patients as late as day 42 although radical
treatment with single dose of PQ (0.75 mg/kg) was given
on last day of treatment. PQ use is however contra-
indicated in pregnant women and children aged < one
year.clearance in studies of the National Antimalarial Drug
PCT (hours)
FU WTH PV PF* Surv 95% CI < 24 24- < 48 48- < 72 ≥ 72
8 1 10 74.1 61.0, 84.7 25 26 12 6
7 0 5 81.0 68.6, 90.1 47 15 1 0
5 0 9 78.6 59.0, 91.7 15 18 2 2
ent failure, LCF, late clinical failure, LPF late parasitological failure, LFU loss to
n, PV protocol violation.
on day 1, 2 or 3 in the presence of parasitaemia; parasitaemia level on day 2
ay 0; parasitaemia on day 3 plus fever.
.
Table 3 Risk of Plasmodium falciparum treatment failure among patients in studies of the National Antimalarial Drug
Resistance Monitoring System, northeast India, 2012-2013
Predictor Value Faila ACPR Risk RR 95% CI
Artesunate dose (mg/kg) ≥ 3.5 24 84 0.222
3.0-3.5 5 21 0.192 0.64 0.19, 2.19
< 3.0 3 7 0.300 1.35 0.49, 3.71
Age < 5 13 18 0.419 2.17 1.11, 2.46
(years) 5-15 11 46 0.193 1.35 0.58, 3.11
≥ 15 8 48 0.143 –
Parasite count < 5000 6 38 0.136 0.65 0.28, 1.53
(/μL) 5000 - 50000 17 64 0.210 0.44 0.23, 0.84
≥ 50000 9 10 0.474 –
#Antifolate Wild 0 0 0.000 –
mutations 1-2 0 6 0.000 –
3-4 5 11 0.313 1.48 0.65, 3.34
5-6 22 82 0.212 0.68 0.29, 1.53
7-8 5 11 0.313 –
Fever Yes 25 73 0.255 1.68 0.78, 3.59
(≥ 37.5°C) No 7 39 0.152 –
Previous Yes/unknown 17 69 0.198 0.76 0.42, 1.41
Drug intake No 15 43 0.259 –
Abbreviations: ACPR adequate clinical and parasitological response, RR relative Risk, CI confidence interval, #dhfr + dhps.
a25 patients were excluded from the analysis as confirmed by PCR.
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genotyped for dhfr and dhps mutation analysis. In dhfr,
double (n = 71) and triple mutations (n = 69) were com-
mon. The most frequent haplotype was double mutant
108/59 followed by triple mutant 108/59/51. Only five
isolates were single mutant while three were found to
have quadruple mutation (5.2%).
In dhps, triple (n = 75) and quadruple mutations (n = 35)
were common. Mutations in codon 437 and 540 were
most frequent and the most frequent haplotype was triple
mutant 540/437/436 followed by quadruple mutant 581/
540/437/436 (Table 5).
Among the 32 PCR-corrected treatment failures, two
samples were not amplified, one was dhfr quadruple
mutant, 21 were triple mutants, seven were double mu-
tants and one was single mutant. However, seven samples
were dhps quadruple mutant, 14 triple mutants, eight
were double, and one was single mutant.Table 4 Gametocyte carriage detected by microscopy in patie
S No State District Gametocytes/μl (%)
D0 D7
1 Tripura Gomati 17/69 (24.6) 22/69 (31.9)
2 Mizoram Lunglei 1/63 (1.6) 2/63 (3.2)
3 Arunachal Pradesh Changlang 12/37 (32.4) 0/37 (0)Interestingly, pfdhfr L164 mutation has been observed
in three out of 11 treatment failures in Lunglei, two out
of 15 treatment failures in Gomati and in Changlang dis-
trict. Earlier, pfdhfr L164 mutation has been found to be
associated with higher level of SP resistance in addition
to decreased efficacy of chloroguanil/dapsone. Also dhps
T613, G581 and A436 have also been observed at all the
three sites, majority in ACPR samples except one
G581dhps mutation in treatment failure sample out of
the total four failures in Changlang district.
Discussion
The sentinel site monitoring studies at three sites in
northeastern region indicate that the efficacy of the
ACT (i.e., AS + SP) recommended for P. falciparum mal-
aria was declining. The treatment failure rates above the
10% threshold warranted a change of drug policy in the
region. These treatment failures were mostly LTF withnts
D14 D21 D28 D35 D42
20/69 (29.0) 14/69 (20.3) 6/69 (8.7) - 3/69 (4.3)
0/63 (0) 0/63 (0) 1/63 (1.6) 0/63 (0) 0/63 (0)
1/37 (2.7) 0/37 (0) 0/37 (0) 0/37 (0) 1/37 (2.7)
Table 5 Molecular markers of anti-folate resistance in
Plasmodium falciparum isolates collected through the
National Antimalarial Drug Resistance Monitoring
System, northeast India, 2012-2013
dhfr (N = 155) dhps (N = 155)
Mutations n Haplotype n Haplotype
Quadruple 5 I51/R59/N108/L164 1 A436/G437/E540/A581/T613
35 A436/G437/E540/G581/A613
Triple 69 I51/R59/N108/I164 75 A436/G437/E540/A581/A613
7 N51/R59/N108/L164 6 A436/G437/K540/G581/A613
5 S436/G437/E540/G581/A613
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triple or quadruple mutation in dhfr and dhps genes.
Four ETF were observed at Tripura. These patients re-
ceived optimal dose of AS and SP. As per WHO definition
of suspected artemisinin resistance, increased parasite
clearance as evidenced by > 10% of cases with parasites
detectable on day 3 following treatment with an ACT war-
rants studies to confirm presence of artemisinin resist-
ance. However, the proportion of patients remaining
parasite positive at day 3 in these studies was much below
the cut-off prescribed by WHO. In addition, artemisinin
efficacy studies are being undertaken at two of these sites
to confirm the efficacy of artemisinin in the region. It is
worth mentioning that three out of four patients were
below the age of five years and had higher frequency of
quintuple mutation as compared to patients with ACPR,
confirming the role of host immunity.
This study provides the first report on the emerging
treatment failure of AS + SP in remote areas of the
country, including areas directly across the border from
Bangladesh and Myanmar where artemisinin resistance
has been confirmed recently. Treatment failure to this
ACT is now evident at all the three study sites of northeast
India. The failure of AS + SP was likely as the molecular
marker of partner drug resistance showed increasing trend
since 2009 in the nationwide sentinel site monitoring
where 20% random samples were assayed to monitor drug
resistance at molecular level. The trend showed increase
from single to double mutation in majority of the samples.
These studies were part of nationwide sentinel sitemonitoring system, where 15 sentinel sites are being mon-
itored across the country to ascertain the efficacy of rec-
ommended anti-malarials against the predominant species
of Plasmodium.
Based on the results of this study, the expert committee
of the NVBDCP created the first subnational drug policy
for India and selected artemether plus lumefantrine as the
new first-line treatment in the northeast [24].
ACT treatment failure > 10% is the cost-effective thresh-
old and requires change of treatment policy for malaria
along with continuous monitoring in adjacent areas [20].
In the present study high treatment failure of AS + SP was
observed at all the three sites ranging between 17 and
23%. A recent study conducted in the neighbouring area
of northeast also showed AS + SP treatment failure of
9.5% [25]. This indicates that the reported treatment
failure of AS + SP is frequent and widespread as the sites
were present in four distant corners of the region and thus
is likely to be present in between areas as well. The treat-
ment failures reported in the study could be due to resist-
ance to partner drug SP as there has been long history
of use and documented SP failure in the region [5]. Also,
irrational treatment practices as well as non-availability of
age-based combi blister packs for children might have
caused drug pressure in the population leading to failure of
partner drug [26,27]. However, combination therapy with
ineffective partner drug is equivalent to artemisinin mono-
therapy on a large scale.
Until recently, the efficacy and safety of recommended
ACT (AS + SP) was high at multiple sites in the country
[28]. The nationwide sentinel site monitoring system con-
ducted 40 studies up to 2011 and the efficacy of AS + SP
during 28 days’ follow-up was above WHO recommended
cut-off for treatment failure at all the sites. The nationwide
sentinel site system also monitored partner drug resist-
ance through molecular studies given the long half life of
SP to detect emerging resistance. Despite low prevalence
of treatment failures to AS + SP, molecular markers of
partner drug resistance were monitored to capture early
signs of treatment failure. Emerging increasing trend of
partner drug resistance markers and to capture LTF, if
any, follow-up in the sentinel site monitoring system was
extended to 42 days since 2012. Until 2010, dhps remained
wild in majority of the samples, however, increasing trend
in dhps point mutations were observed later, particularly
in northeastern region. These findings prompted more
focus in northeastern region. Thus, three sites at different
ecological conditions were selected and efficacy of AS + SP
in P. falciparum was studied.
Data on molecular studies for SP resistance are conclu-
sive with increased frequency of quintuple mutation over
time. Increased frequency of quadruple mutation in dhfr
and dhps gene was observed from all the three study
sites with higher frequency in dhps gene. Sulphadoxine
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http://www.malariajournal.com/content/13/1/284resistance in P. falciparum is associated with mutations at
five pfdhps codons; 436ala/phe, 437gly, 540glu, 581gly,
and 613ser [10]. The pfdhps mutation at codon A436
causes alteration in binding of sulphadoxine followed by
sequential mutations at G437, E540, G581, and T/S613
which may cause increase in sulphadoxine resistance [29].
Mutation at codon G581 along with 437 and 540 may be
associated with earlier treatment failure [30].
A strong indicator for SP treatment failure is the quin-
tuple mutations in three pfdhfr codons (108asn + 51ile +
59arg) and two pfdhps codons (437gly + 540glu) [31].
Quintuple mutation has been observed in 39% of treat-
ment failure samples at all the three sites with highest in
Tripura, confirming the role of SP failure. In the present
study, quintuple as well as more combination of muta-
tions have been observed at all the three sites with high-
est in Tripura. Similarly, high prevalence of quintuple
mutation (35%) has been observed in samples collected
from Kolkata [25].
Following these findings, further new studies on track-
ing resistance to artemisinin are being undertaken at two
sites in this region. Recently association of K13-propeller
polymorphism with artemisinin resistance in vitro and
in vivo has been proposed [32]. Further studies to map
K13 gene polymorphism, in addition to the clinical pheno-
type of slow clearance, are being undertaken.
Various factors including host immunity and pharma-
cokinetics of the drug play an important role in achiev-
ing complete cure or treatment failure in patients. In the
present study, younger age category (<five years) relative
to adults 15 years or older, fever at enrolment and low
administered dose of AS (< 3 mg/kg, 3–3.5 mg/kg) relative
to 3.5 mg/kg or more were associated with higher risk of
treatment failure. Negative correlation was observed
between the risk of failure with the dose of AS (in mg/kg
body weight). Although, the recommended daily dose of
AS is 4 mg/kg, 15.6% of treatment failure patients received
3.0 to < 3.5 mg of AS per kg, and 9.4% received < 3.0 mg/
kg. Due to variation in body weight within age categories,
dosing of drugs based on age category presents the risk of
under-dosing or over-dosing. Thus, the criteria to use age
rather than body weight for calculating the dose of anti-
malarial needed for a patient is the probable cause of sub-
optimal dosing. However, optimal or higher dose of SP
was observed in majority of the patients with only 9.4%
patients receiving under-dose of SP. Fever at enrolment
was positively and significantly associated with treatment
failures. Earlier results of nation-wide sentinel system also
observed younger age, fever and low AS dose as the po-
tential risk factors for treatment failure [28]. Partner drug
resistance markers are well defined and can ascertain the
falling efficacy of the administered drug. The relative risk
was highest with the presence of triple or quadruple muta-
tion, which signifies the role of SP in treatment failure.Parasite clearance time is multifactorial and is affected by
initial parasite load, host immunity, pharmacokinetics of
the drug. No significant difference in mean parasitaemia,
dose of AS at enrolment or any adverse event reported
was observed between the patients who had parasit-
aemia ≥ 72 hours with those who cleared parasite within
48 hours. Host immunity had a definite role as six out of
eight patients were less than five years of age. Also, poor
absorption of drug in individuals may play a role in
delayed PCT besides immunity. However, there were
insufficient observations to determine the risk factors for
parasite clearance interval of ≥ 72 hours.
Recently increasing failure rates of artesunate meflo-
quine in Thailand and dihydroartemisinin piperaquine in
Cambodia have been reported [16,33]. With increasing
cases of ACT failure, more studies to optimize the dose
and duration of recommended ACT or new combination
is required. The newly recommended ACT: artemether-
lumefantrine (AL) has been used by neighbouring coun-
tries in the past; hence cross-border monitoring of AL
with countries that use this regimen is urgently required.
In addition, the newly introduced ACT in the region has
certain challenges as the compliance to twice daily regi-
men and the fat dependant absorption in diet need to be
considered besides the molecular markers for lumefan-
trine, as well as other partner drugs. Expanded in vitro
monitoring in the northeast for early warning of this
ACT is required.
Conclusions
The efficacy of AS + SP was declining in northeast India
and exceeded the threshold for changing drug policy.
Based on the results of the study, the expert committee of
the National Vector Borne Disease Control Programme
formulated the first subnational drug policy for India and
selected artemether plus lumefantrine as the new first-line
treatment in the northeast. Continued monitoring of anti-
malarial drug efficacy in northeastern region is essential
for effective malaria control.
Limitations
The nation-wide sentinel site monitoring system created
in 2009 accelerated the assessment of emerging ACT
treatment failure in areas with international borders and is
vigilant to detect delayed parasite clearance, if any. Few of
the earlier reported limitations of nationwide sentinel sys-
tem were overcome during 2012. Firstly, follow-up was ex-
tended up to 42 days, delayed parasitaemia was monitored
by looking at parasite clearance interval of ≥ 72 hours;
partner drug resistance markers were analysed in all the
isolates. The other limitations include 24 hours sampling
for parasite monitoring, as the patients were from distant
places. The sample size was relatively low in Changlang
district, Arunachal Pradesh. To ascertain the role of
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http://www.malariajournal.com/content/13/1/284partner drug resistance, drug levels of SP could not be
done as the samples for drug concentration could not be
collected.
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